Newsletter | July 15, 2026

07.15.26 -- Where Enzymatic Ligation Of siRNA Stands Today

FEATURED EDITORIAL

Stitching The Future: Where Enzymatic Ligation Of siRNA Stands Today

Is enzymatic ligation a futuristic dream or a current commercial reality? In this segment, industry experts Claire McCleod and Jill Caswell explore how the sector has moved past the proof-of-concept stage into early commercialization and what this looks like/means for early adopters today. 

Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics

As siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.

Beyond The Liver: How Machine Learning-Optimized LNPs Are Expanding RNA Delivery Into Adipose Tissue

Machine learning-guided LNP design is enabling targeted RNA delivery to adipose tissue, opening new possibilities for obesity, metabolic disease, and beyond.

INDUSTRY INSIGHTS

mRNA Immunogenicity: Early Assessment Of Human Immune Response

Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA.

Expand Your Toolbox For Quality mRNA Manufacturing

Explore guidelines for the use of SP6 RNA Polymerase in mRNA synthesis and your mRNA production processes, as well as guidelines you can use to determine if SP6 RNA Polymerase is a good alternative.

Effective Strategies To Minimize Product Loss During Fill Finish

Every drop of high-value biologic lost in fill finish is money left on the table. Gain insight into practical strategies to protect your yield.

LYO Cycle Development Ensures Success For Oncology Drug Scale-Up

An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

Intelligent mRNA Manufacturing Through Process Analytical Technologies

Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.

Purification And QC Of An RNA 21‑Mer Oligonucleotide Via LC‑MS

See how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.

SOLUTIONS

Lipids CDMO Services: Custom Excipients Tailored To Your Needs

Automated Screening System For Lipid Nanoparticle Formulation

The Most Comprehensive Supply Chain Solutions For The Industry